Krystal Biotech Inc
KRYS
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
21.6% upsideUndervalued by 21.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.11 Billion |
|---|---|
| Enterprise Value | $8.61 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $7.08 |
| Beta | 0.5 |
| Outstanding Shares | 29,288,000 |
Return
| Return on Equity | 17.63% |
|---|---|
| Return on Assets | 16.11% |
| Return on Invested Capital | 13.87% |
Valuation & Multiples
| P/E Ratio | 40.22 |
|---|---|
| PEG | 71.15 |
| Price to Sales | 21.56 |
| Price to Book Ratio | 7.02 |
| Enterprise Value to Revenue | 20.63 |
| Enterprise Value to EBIT | 48.16 |
| Enterprise Value to Net Income | 38 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3802▼ 2.78% |
|---|---|
| Total Calls | 310,100▲ 44.43% |
| Total Puts | 117,900▲ 34.59% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 98.00%▼ 0.21% |
|---|---|
| Total Invested | $7.32B▲ 4.49% |
| Investors Holding | 377▲ 33.00% |
ESG Score
No data
About Krystal Biotech Inc
Relevant Senate Committees
Has direct authority over tax policy (impacting corporate profitability) and entitlement spending, including Medicare pricing, which significantly influences revenue for biological product manufacturers.
Directly controls the allocation of federal funding to agencies like NIH (research) and FDA (regulatory oversight), and potentially VA (procurement), which are vital for the biotech sector.
Directly regulates the FDA (responsible for biological product approval) and oversees NIH funding for biomedical research, making it a primary driver of the biotech sector's regulatory and funding environment.
Has direct jurisdiction over intellectual property (patents), which is fundamental to the value and business model of biological product manufacturers like Krystal Biotech. Antitrust oversight also impacts industry consolidation.